Loading stock data…
TNXP
$13.60+0.67 (+5.18%)
Market ClosedLast close May 1
Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Tonix Pharmaceuticals Holding Corp. in the Healthcare sector is trading at $13.60. The stock is currently near its 52-week low of $11.60, remaining 37.5% below its 200-day moving average. Technical signals show neutral RSI of 55 and bullish MACD crossover, explaining why TNXP maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 55) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$13.60
Potential Upside
5%
Whystock Fair Value$14.28
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus3 analysts
Mean target$54.33+299.5%
Range$34.00 – $65.00
Fundamentals
Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$177.43M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.76
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-44.09%
Volume
Today's trading volume
366,629
Recent News
Tonix prices 615,025 shares at $16.26 in registered direct offering
Tonix Pharmaceuticals (TNXP) entered into a securities purchase agreement with Point72 for the purchase and sale of 615,025 shares of its common stock at an offering price of $16.26 per share and, in lieu of shares of common stock, pre-funded warrants to purchase up to an aggregate of 615,025 shares of common stock at a purchase price of $16.259 per pre-funded warrant, which equals the offering price per share of the common stock less the $0.001 per share exercise price of each pre-funded warran
Several Insiders Invested In Tonix Pharmaceuticals Holding Flagging Positive News
Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...
Tonix Pharmaceuticals Holding Corp (TNXP) Showcases Promising TNX-801 Vaccine Data
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) is one of the top long-term biotechnology stocks to buy. On October 17, Tonix Pharmaceuticals (NASDAQ:TNXP) presented encouraging preclinical data for its investigational mpox and smallpox vaccine candidate, TNX-801, at the World Vaccine Congress Europe 2025. The live, attenuated horsepox-based vaccine elicited strong immune responses, provided long-term protection, and demonstrated […]
Will the first fibromyalgia drug in 15 years deliver a breakthrough in pain?
The new treatment may only offer modest benefits, but could gain traction in a market with few other options.
FDA Approves New Fibromyalgia Drug, But Tonix Shares Slide
Tonix Pharmaceuticals reported late Friday that the Food and Drug Administration had approved its Tonmya treatment for fibromyalgia. Fibromyalgia, a condition affecting 10 million adults in the U.S., mainly women, causes chronic pain and fatigue. Tonix shares opened down 14% following the FDA news and a Monday morning press conference.